ASCO Poster has gone live: http://cellceutix.com/
Post# of 72447
Posted On: 06/03/2013 9:23:22 AM
Initial Takeaways from the poster:
The Phase 1 trial began November 7, 2012.
•A total of 10 patients have been enrolled to date.
•Cohorts 0, 1 and 2 have been completed without DLT.
•The MTD has not yet been reached; the trial is ongoing
Very wide range of patients with solid tumors being tested (liver, lungs, overian, pancreatic, etc etc), one person has completed 7 cycles!
No DLT confirmed so far through first 3 cohorts, let's not lose sight of this very important and positive confirmation!!!
The Phase 1 trial began November 7, 2012.
•A total of 10 patients have been enrolled to date.
•Cohorts 0, 1 and 2 have been completed without DLT.
•The MTD has not yet been reached; the trial is ongoing
Very wide range of patients with solid tumors being tested (liver, lungs, overian, pancreatic, etc etc), one person has completed 7 cycles!
No DLT confirmed so far through first 3 cohorts, let's not lose sight of this very important and positive confirmation!!!
New PR to go along with ASCO Presentation:
Beverly, MA — 06/03/13 — Cellceutix Corporation (OTCBB: CTIX) (the “Company”), a clinical stage biopharmaceutical company focused on discovering small molecule drugs to treat unmet medical conditions, including drug-resistant cancers and autoimmune diseases, announces that it has published its poster on Kevetrin, the Company’s p53 modulating drug, being presented at 8:00 AM ET today at the 2013 American Society of Clinical Oncology (“ASCO”) Annual Meeting being held in Chicago, Illinois from May 31 through June 4, 2013.
The poster summarizes information from the ongoing Phase I trial being conducted at Harvard Cancer Centers, including Dana-Farber Cancer Institute, Beth Israel Deaconess Medical Center and Massachusetts General Hospital. Research is characterizing the pharmacokinetic profile of Kevetrin, along with evaluating preliminary evidence of anti-tumor activity and potential biomarkers of tumor response to Kevetrin by activation of p21.
The presentation is available for viewing at: http://cellceutix.com/events/
Cellceutix wishes to commend the efforts of Dr. Geoffrey Shapiro, Dr. Jeff Supko, Dr. Daniel Cho and their teams in the clinical trial and poster presentation. The Company considers itself fortunate to be working with such world-renown leaders in oncology trials and research.
“The trial, which is currently in the fourth cohort, is progressing with data to date on par with our laboratory studies,” commented Dr. Krishna Menon, Chief Scientific Officer at Cellceutix. “Through three completed cohorts, we have seen no signs of dose limiting toxicity. Dana-Farber’s extensive tumor mapping technologies will help us pinpoint which patients will benefit the most from Kevetrin as we move towards defining the Maximum Tolerated Dose. We are very pleased with the results so far and believe that as dose escalation continues, the potential therapeutic benefits will rise significantly.
Dr. Menon continued, “Some very exciting times are approaching as we expect to reach Maximum Tolerated Dose between the sixth and ninth cohorts. We also look forward to data on the p21 biomarker, which was not available for the ASCO meeting as the laboratory moves the samples into queue, in the coming weeks. As can clearly be seen in the poster, at this time ten patients have been treated with Kevetrin at low doses. Five patients have received more than one cycle of Kevetrin, including one patient who has already completed seven dosing cycles. This lends to our enthusiasm about the potential of Kevetrin and our sanguine outlook for the second half of the year.”
So, no P21 data available yet which many were hoping for, but this is very good news, about as good as we can hope for, short of announcing P21 data is available :
“The trial, which is currently in the fourth cohort, is progressing with data to date on par with our laboratory studies,” commented Dr. Krishna Menon, Chief Scientific Officer at Cellceutix.
We all know how the lab studies went, and if human results so far are on par with lab results.
Beverly, MA — 06/03/13 — Cellceutix Corporation (OTCBB: CTIX) (the “Company”), a clinical stage biopharmaceutical company focused on discovering small molecule drugs to treat unmet medical conditions, including drug-resistant cancers and autoimmune diseases, announces that it has published its poster on Kevetrin, the Company’s p53 modulating drug, being presented at 8:00 AM ET today at the 2013 American Society of Clinical Oncology (“ASCO”) Annual Meeting being held in Chicago, Illinois from May 31 through June 4, 2013.
The poster summarizes information from the ongoing Phase I trial being conducted at Harvard Cancer Centers, including Dana-Farber Cancer Institute, Beth Israel Deaconess Medical Center and Massachusetts General Hospital. Research is characterizing the pharmacokinetic profile of Kevetrin, along with evaluating preliminary evidence of anti-tumor activity and potential biomarkers of tumor response to Kevetrin by activation of p21.
The presentation is available for viewing at: http://cellceutix.com/events/
Cellceutix wishes to commend the efforts of Dr. Geoffrey Shapiro, Dr. Jeff Supko, Dr. Daniel Cho and their teams in the clinical trial and poster presentation. The Company considers itself fortunate to be working with such world-renown leaders in oncology trials and research.
“The trial, which is currently in the fourth cohort, is progressing with data to date on par with our laboratory studies,” commented Dr. Krishna Menon, Chief Scientific Officer at Cellceutix. “Through three completed cohorts, we have seen no signs of dose limiting toxicity. Dana-Farber’s extensive tumor mapping technologies will help us pinpoint which patients will benefit the most from Kevetrin as we move towards defining the Maximum Tolerated Dose. We are very pleased with the results so far and believe that as dose escalation continues, the potential therapeutic benefits will rise significantly.
Dr. Menon continued, “Some very exciting times are approaching as we expect to reach Maximum Tolerated Dose between the sixth and ninth cohorts. We also look forward to data on the p21 biomarker, which was not available for the ASCO meeting as the laboratory moves the samples into queue, in the coming weeks. As can clearly be seen in the poster, at this time ten patients have been treated with Kevetrin at low doses. Five patients have received more than one cycle of Kevetrin, including one patient who has already completed seven dosing cycles. This lends to our enthusiasm about the potential of Kevetrin and our sanguine outlook for the second half of the year.”
So, no P21 data available yet which many were hoping for, but this is very good news, about as good as we can hope for, short of announcing P21 data is available :
“The trial, which is currently in the fourth cohort, is progressing with data to date on par with our laboratory studies,” commented Dr. Krishna Menon, Chief Scientific Officer at Cellceutix.
We all know how the lab studies went, and if human results so far are on par with lab results.
(0)
(0)